Stocks › HUMA
Humacyte, Inc.
HUMA·Nasdaq·
United States·USD
$0.45
-0.10 (-17.90%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
HUMA
Humacyte, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HUMAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of HUMA by members of U.S. Congress · 17 on record · 5 in the last 12 months
Whale Activity
Position changes in HUMA reported for 2026-09-30 by 176 institutional filers
- Increased38
- New12
- Held39
- Decreased38
- Closed46
- No prior filing3
| Filer | Shares | Value | Change |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 11.0M | $5.7M | increased |
| ANTIPODES PARTNERS Ltd | 8.3M | $4.3M | decreased |
| BlackRock, Inc. | 4.6M | $2.4M | decreased |
| GREAT POINT PARTNERS LLC | 3.8M | $1.9M | held |
| MARSHALL WACE, LLP | 3.0M | $1.6M | increased |
| UBS Group AG | 3.0M | $1.6M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7M | $1.4M | increased |
| CITADEL ADVISORS LLC | 1.7M | $897K | increased |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.7M | $865K | decreased |
| VANGUARD FIDUCIARY TRUST CO | 1.6M | $829K | increased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.4M | $712K | increased |
| Endowment Wealth Management, Inc. | 105.4K | $505K | held |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by HUMA insiders, by quarter · Form 4
Recent Insider Transactions
163 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Jones Keith AnthonyDirector | Purchase | +10.0K | $0.56 | $6K | Sep 14, 2026 | Form 4 ↗ |
| Jones Keith AnthonyDirector | Purchase | +10.0K | $0.69 | $7K | Aug 20, 2026 | Form 4 ↗ |
| Jones Keith AnthonyDirector | Purchase | +30.0K | $0.59 | $18K | Aug 17, 2026 | Form 4 ↗ |
| Sebelius KathleenDirector | Purchase | +56.8K | $0.88 | $50K | May 19, 2026 | Form 4 ↗ |
| Parikh Shamik JChief Medical Officer | Sale | −45.9K | $0.90 | $41K | May 18, 2026 | Form 4 ↗ |
| Sander Dale A.CFO and Chief Corp. Dev. Off | Sale | −45.9K | $0.90 | $41K | May 18, 2026 | Form 4 ↗ |
| Constantino Michael T.Director | Purchase | +11.0K | $0.89 | $10K | May 18, 2026 | Form 4 ↗ |
| Sander Dale A.CFO and Chief Corp. Deve. Off. | Grant / award | +311.1K | $0.00 | $0 | Nov 16, 2025 | Form 4 ↗ |
| Parikh Shamik JChief Medical Officer | Grant / award | +311.1K | $0.00 | $0 | Nov 16, 2025 | Form 4 ↗ |
| Dougan Brady WDirector | Sale | −591.7K | $1.58 | $935K | Aug 20, 2025 | Form 4 ↗ |
| Niklason Laura EPresident, CEO and Director · Director | Sale | −591.7K | $1.58 | $935K | Aug 20, 2025 | Form 4 ↗ |
| Dougan Brady WDirector | Sale | −1.1M | $1.63 | $1.8M | Aug 19, 2025 | Form 4 ↗ |
| Niklason Laura EPresident, CEO and Director · Director | Sale | −1.1M | $1.63 | $1.8M | Aug 19, 2025 | Form 4 ↗ |
| Dougan Brady WDirector | Sale | −549.4K | $1.83 | $1.0M | Aug 18, 2025 | Form 4 ↗ |
| Niklason Laura EPresident, CEO and Director · Director | Sale | −549.4K | $1.83 | $1.0M | Aug 18, 2025 | Form 4 ↗ |
| Scheessele William JohnChief Commercial Officer | Purchase | +6,493 | $1.54 | $10K | Apr 14, 2025 | Form 4 ↗ |
| Sander Dale A.CFO and Chief Corp. Deve. Off. | Purchase | +20.0K | $1.53 | $31K | Apr 10, 2025 | Form 4 ↗ |
| Parikh Shamik JChief Medical Officer | Purchase | +7,500 | $1.55 | $12K | Apr 10, 2025 | Form 4 ↗ |
| Sebelius KathleenDirector | Purchase | +50.0K | $1.32 | $66K | Apr 8, 2025 | Form 4 ↗ |
| Green Charles BruceDirector | Purchase | +6,000 | $1.29 | $8K | Apr 8, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding HUMA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 7.7M | $6.0M | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $1.7M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $1.3M | 0.00% | Apr 30, 2026 |
| iShares Biotechnology ETF iShares Trust | 1.4M | $1.1M | 0.01% | Jun 30, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 835.7K | $1.1M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 969.6K | $583K | 0.00% | Aug 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 860.9K | $518K | 0.00% | Aug 31, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 575.4K | $346K | 0.00% | Aug 31, 2026 |
| Schwab Small-Cap Index Fund SCHWAB CAPITAL TRUST | 370.4K | $312K | 0.00% | Apr 30, 2026 |
| Schwab Total Stock Market Index Fund SCHWAB CAPITAL TRUST | 415.2K | $271K | 0.00% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list HUMA's shares (CUSIP 44486Q103), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Fresenius Medical Care AGSCHEDULE 13D/A · activist (13D) · 13.6M shares4.9%
Aug 18, 2026 · ↗ - Fresenius Medical Care Holdings, Inc.SCHEDULE 13D/A · activist (13D) · 13.6M shares4.9%
Aug 18, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 4.1M shares1.5%
Jul 28, 2026 · ↗ - Fresenius Medical Care AGSCHEDULE 13D/A · activist (13D) · 18.3M shares6.8%
Jul 13, 2026 · ↗ - Fresenius Medical Care Holdings, Inc.SCHEDULE 13D/A · activist (13D) · 18.3M shares6.8%
Jul 13, 2026 · ↗ - Anthony A. YoseloffSCHEDULE 13G · passive (13G) · 12.8M shares4.7%
Jun 22, 2026 · ↗ - Davidson Kempner Capital Management LPSCHEDULE 13G · passive (13G) · 12.8M shares4.7%
Jun 22, 2026 · ↗ - Davidson Kempner Arbitrage, Equities & Relative Value LPSCHEDULE 13G · passive (13G) · 12.6M shares4.7%
Jun 22, 2026 · ↗ - M.H. Davidson & Co.SCHEDULE 13G · passive (13G) · 232.7K shares0.1%
Jun 22, 2026 · ↗ - Fresenius Medical Care AGSCHEDULE 13D/A · activist (13D) · 18.3M shares6.8%
Jun 15, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming humacyte as client
- CAPITOL HILL CONSULTING GROUPHUMACYTE · 2026 Q3 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2026 Q2 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2026 Q1 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2025 Q4 · MMM, HCR, DEF$50K
Filing ↗ - CAPITOL HILL CONSULTING GROUPHUMACYTE · 2025 Q3 · MMM, HCR, DEF$50K
Filing ↗
Government Contracts
Federal awards to Humacyte, Inc. · USAspending
No federal contract awards found for Humacyte, Inc..
U.S. Patents
Recent USPTO applications naming Humacyte, Inc.
No USPTO patent applications found for Humacyte, Inc..
Annual Financials
From HUMA's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | n/a | n/a | n/a |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$84.6M | -$81.2M |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M | -$26.5M |
| Diluted EPS | -$0.26 | -$1.26 | -$1.07 | -$0.12 | -$0.66 |
| Operating cash flow | -$105.0M | -$98.1M | -$73.3M | -$71.1M | -$81.2M |
| Cash and equivalents | $50.5M | $44.9M | $80.4M | $149.8M | $217.5M |
| Total assets | $116.4M | $137.9M | $128.2M | $204.3M | $286.5M |
| Total liabilities | $113.3M | $190.5M | $114.7M | $87.4M | $164.4M |
| Shareholders' equity | $3.1M | -$52.7M | $13.5M | $116.9M | $122.2M |
As Humacyte, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 27, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in HUMA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsNov 10, 2026
EDGAR ↗ - 8-K · Items 5.02, 7.01, 9.01Officer / director change · Reg FD disclosureSep 28, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 12, 2026
EDGAR ↗ - 8-K · Items 3.01Delisting noticeJul 31, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 11, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 10, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteJun 9, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsJun 5, 2026
EDGAR ↗ - 8-K · Items 3.01Delisting noticeMay 8, 2026
EDGAR ↗
About Humacyte, Inc.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersDURHAM, NC
IncorporatedDE
SEC CIK0001818382 ↗
Former namesAlpha Healthcare Acquisition Corp.

